This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
CVS Health's (CVS) Digital Focus Aids Growth, Macro Issues Ail
by Zacks Equity Research
CVS Health's (CVS) Health Care Benefits segment demonstrates value to consumers and clients by successfully managing drug cost trends and bringing innovative clinical solutions to the market.
Walgreens (WBA) Launches Rx Savings Finder Digital Tool
by Zacks Equity Research
Walgreens (WBA) introduces Rx Savings Finder to help patients save on prescription medications.
Thermo Fisher (TMO) Extends Partnership With Flagship Pioneering
by Zacks Equity Research
Thermo Fisher's (TMO) in-depth knowledge of the life sciences sector will be combined with Flagship Pioneering to create revolutionary capabilities for the ecosystem.
Charles River (CRL) Gains on Price & Volume Growth Amid FX Woe
by Zacks Equity Research
At present, Charles River (CRL) is the largest provider of outsourced drug discovery, non-clinical development and regulated safety testing services worldwide.
Inspira (IINN) Expands in Life Support Space With New Deal
by Zacks Equity Research
According to Inspira (IINN), the integration of its technology to oxygenate blood combined with Ennocure's infection prevention solutions is likely to help improve patient outcomes in ICUs.
Haemonetics (HAE) Loses -6.71% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
The heavy selling pressure might have exhausted for Haemonetics (HAE) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Penumbra (PEN) Enrolls First Patient in Landmark STORM-PE Trial
by Zacks Equity Research
Penumbra (PEN) achieves an important milestone by enrolling the first patient in STORM-PE RCT.
Reasons to Retain Quest Diagnostics (DGX) Stock for Now
by Zacks Equity Research
Investors are optimistic about Quest Diagnostics (DGX) on the strength of the base business.
Here's Why You Should Retain Zimmer Biomet (ZBH) for Now
by Zacks Equity Research
Investors are optimistic about Zimmer Biomet (ZBH), driven by a recovery in business and an expanding global footprint.
Quest Diagnostics' (DGX) New Pact to Scale Precision Medicine
by Zacks Equity Research
Quest Diagnostics' (DGX) will supply next-generation sequencing and enhanced RNA extraction services for Scipher's PrismRA test through a new collaboration.
Charles River (CRL) Backs the Quest to Cure SPG56 via New Deal
by Zacks Equity Research
Charles River (CRL) and GC4K announce a gene therapy manufacturing collaboration.
3 Reasons Why Growth Investors Shouldn't Overlook Haemonetics (HAE)
by Zacks Equity Research
Haemonetics (HAE) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Smith & Nephew (SNN) New Buyout Expands Sports Medicine Suite
by Zacks Equity Research
Smith & Nephew (SNN) will pay an initial cash consideration of $180 million at closure, with an additional $150 million based on financial performance to acquire CartiHeal.
Penumbra's (PEN) Expansion Moves, New Launches Aid Growth
by Zacks Equity Research
Penumbra (PEN) expects to materially increase both revenues and profitability of the international business in the next three years and beyond.
Bruker's (BRKR) New Collaboration to Use MALDI Biotyper System
by Zacks Equity Research
Bruker (BRKR) and Accelerate Diagnostics are set to work together to bring rapid, automated microbial identification directly from positive blood culture samples.
Here's Why You Should Retain Teleflex (TFX) Stock for Now
by Zacks Equity Research
Investors remain optimistic about Teleflex (TFX) on the strength of the Vascular and Interventional businesses.
Haemonetics (HAE) Stock Up 4.2% YTD: Will the Rally Continue?
by Zacks Equity Research
Investors are optimistic about Haemonetics (HAE), driven by a strategic focus on establishing leading positions in high-growth markets and raised guidance.
Haemonetics' (HAE) Plasma Growth, Innovation Aid Performance
by Zacks Equity Research
Haemonetics' (HAE) hospital portfolio is evolving and helping to create new opportunities for growth and diversification.
Here's Why Investors Should Retain Labcorp (LH) Stock for Now
by Zacks Equity Research
Investors are increasingly optimistic about Labcorp (LH) due to development in targeted high-growth areas.
Orthofix (OFIX) Q3 Earnings Top Estimates, 2023 Sales View Cut
by Zacks Equity Research
Orthofix (OFIX) saw very strong growth across multiple business segments and product lines in Q3.
Labcorp (LH) Closes the Legacy Health Asset Acquisition Deal
by Zacks Equity Research
Labcorp (LH) finalizes the comprehensive laboratory relationship with Legacy Health.
Here's Why Haemonetics (HAE) is a Strong Growth Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
EssilorLuxottica (ESLOY), Moncler Ink Luxury Eyewear Deal
by Zacks Equity Research
The first Moncler Lunettes collection produced with EssilorLuxottica (ESLOY) is called Fall-Winter 2024.
Here's Why You Should Retain Edward Lifesciences (EW) Stock Now
by Zacks Equity Research
Investors remain optimistic about Edward Lifesciences (EW) due to Surgical's differentiated portfolio and TMTT franchise.
Quest Diagnostics' (DGX) New Pact to Advance Cancer Screening
by Zacks Equity Research
Quest Diagnostics' (DGX) latest partnership will increase the likelihood that Americans will eventually have an easy, reliable and accessible way to check for colorectal cancer.